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Sebaceous lipogenesisThe roles of the epidermal growth factor receptor (EGFR) in sebaceous glands remain poorly
explored. We show that human sebocytes express EGFR and lower levels of ERBB2 and ERBB3, all
receptors being downregulated after the induction of lipid synthesis. Nile red staining showed that
siRNA-mediated downregulation of EGFR or ERBB3 increases lipid accumulation, whereas ERBB2
downregulation has no effect. Spectrometry conﬁrmed induction of triglycerides after EGFR or
ERBB3 downregulation and revealed induction of cholesteryl esters after downregulation of EGFR,
ERBB2 or ERBB3. Thus, EGFR/ERBB receptors differentially modulate sebaceous lipogenesis, a key
feature of sebaceous gland physiology and of several skin diseases.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Sebaceous glands (SG) are exocrine glands of the skin most
commonly found in association with a hair follicle. During their
differentiation, sebocytes progressively synthesize and accumulate
lipids within their cytoplasm, and are eventually dislodged from
the periphery to the core of the gland. Once a certain size is
attained, the cell disrupts and releases its contents, a process ter-
med holocrine secretion. The synthesized lipids and cellular debris
reach the skin surface via the hair follicle canal, and represent the
major component of skin sebum [1–3]. Although several functions
have been credited to sebum, including a role in epidermal barrier
and in hair follicle integrity, as well as antibacterial and antioxi-
dant properties [4,5], its exact role remains unclear. However,
increased sebum production is a key component the most common
skin disease, acne [6,7]. Current data indicate that not only the
amount of sebum but also the sebum composition plays a majorrole in the induction of sebaceous gland-associated skin diseases
[8].
Sebocyte differentiation and sebaceous lipogenesis are con-
trolled by numerous hormones, growth factors, and transcription
factors. There is growing evidence suggesting that the epidermal
growth factor receptor (EGFR) and its ligands play an important
role in this process. The EGFR is strongly expressed in the undiffer-
entiated sebocytes at the periphery of mouse [9] and human [10]
sebaceous glands. Stimulation of hamster sebocytes with EGFR
ligands increased proliferation and inhibited sebaceous lipogenesis
[11], and the ligand EGF also impaired lipogenesis in human seba-
ceous glands maintained in vitro [12]. Interestingly, although EGF
is a common medium additive for the culture of isolated human
sebocytes, it does not inﬂuence their proliferation [13], which
points to species-speciﬁc differences in the response of sebocytes
to EGF. More recently, enlarged SGs and increased sebum produc-
tion were reported in transgenic mice overexpressing the EGFR
ligand epigen [14] and in Dsk5 animals, a mouse line in which
the EGFR is constitutively activated independently of ligand
binding [15].
The EGFR (also known as ERBB1 or HER1) belongs to a family of
tyrosine kinase receptors that also includes ERBB2 (NEU, HER2),
ERBB3 (HER3), and ERBB4 (HER4) [16,17]. In contrast to the
EGFR, the expression and function of these related receptors in
sebocytes has not been studied in detail before. Notably, a marked
Table 1
Primers and probes employed for the quantitative RT-PCR analysis.
EGFR Forward primer
Reverse primer
Universal probe
50-gccttgactgaggacagca-30
50-tttgggaacggactggttta-30
#69 (cat. No. 04688686001)
ERBB2 Forward primer
Reverse primer
Universal probe
50-tgctgtcctgttcaccactc-30
50-tcatcctcatcatcttcacattg-30
#67 (cat. No. 04688660001)
ERBB3 Forward primer
Reverse primer
Universal probe
50-ctgatcaccggcctcaat-30
50-ggaagacattgagcttctctgg-30
#37 (cat. No. 04687957001)
ERBB4 Forward primer
Reverse primer
Universal probe
50-gagcaagaattgactcgaatagg-30
50-ttcctgacatgggggtgtag-30
#63 (cat. no. 04688627001)
TGFA Forward primer
Reverse primer
Universal probe
50-ttgctgccactcagaaacag-30
50-atctgccacagtccacctg-30
#63 (cat. No. 04688627001)
AREG Forward primer
Reverse primer
Universal probe
50-cggagaatgcaaatatatagagcac-30
50-caccgaaatattcttgctgaca-30
#38 (cat. No. 04687965001)
EREG Forward primer
Reverse primer
Universal probe
50-tggtctcttcactcaggtctca-30
50-cgtgagttggcatagggaac-30
#86 (cat. No. 04689119001)
HBEGF Forward primer
Reverse primer
Universal probe
50-tggggcttctcatgtttagg-30
50-catgcccaacttcactttctc-30
#55 (cat. No. 04688520001)
EGF Forward primer
Reverse primer
Universal probe
50-aagaatgggggtcaaccagt-30
50-tgaagttggttgcattgacc-30
#27 (cat. No. 04687582001)
BTC Forward primer
Reverse primer
Universal probe
50-actgcatcaaagggagatgc-30
50-tctcacaccttgctccaatg-30
#49 (cat. No. 04688104001)
EPGN Forward primer
Reverse primer
Universal probe
50-tttgggagttccaatatcagc-30
50-tgtgattggaggtgttacagtca-30
#34 (cat. No. 04687671001)
SREBF1 Forward primer
Reverse primer
Universal probe
5’-cgctcctccatcaatgaca-‘3
5’-tgcgcaagacagcagattta-‘3
#77 (cat. no. 04689003001)
FAS Forward primer
Reverse primer
Universal probe
5’-gtggacccgctcagtacg-‘3
5’-ggacgataatctagcaacagacg-‘3
#60 (cat. no. 04688589001)
DGAT2 Forward primer
Reverse primer
Universal probe
5’-caagcccatcaccactgtt-30
50-tcgatgtcttgctgggttg-30
#78 (cat. No. 04689011001)
FADS2 Forward primer
Reverse primer
Universal probe
50-ctacgctggagaagatgcaa-30
50-ttcaagaacttgcccacga-30
#85 (cat. No. 04689097001)
SCD1 Forward primer
Reverse primer
Universal probe
50-cctagaagctgagaaactggtga-30
50-acatcatcagcaagccaggt-30
#82 (cat. No. 04689054001)
SCD5 Forward primer
Reverse primer
Universal probe
50-gacctgcttgctgatcctgt-30
50-ccattcacgaagcatctcac-30
#34 (cat. No. 04687671001)
PLIN2 Forward primer
Reverse primer
Universal probe
50-tcagctccattctactgttcacc-30
50-cctgaattttctgattggcact-30
#72 (cat. No. 04688953001)
PPIA Forward primer
Reverse primer
Universal probe
50-cctaaagcatacgggtcctg-30
50-tttcactttgccaaacacca-30
#48 (cat. No. 04688082001)
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expressing ERBB2 [9], suggesting that ERBBs may be able to mod-
ulate sebocyte differentiation as well. Thus, the aim of this work is
to study the expression and function of the ERBB receptors in sebo-
cytes to uncover their potential functions in the biology of seba-
ceous glands.
2. Materials and methods
2.1. Cell culture
SZ95 sebocytes [18] were routinely cultured in Sebomed med-
ium (Biochrom, Berlin, Germany) supplemented with 10% fetal calf
serum (Biochrom) and 5 lg/l EGF (Biochrom). For the experimental
induction of lipogenesis, cells were cultured in the medium above
lacking EGF for 24 h before supplementation with linoleic acid (LA;
104 M, Merck, Darmstadt, Germany) or vehicle only (DMSO) for
the indicated periods of time.
2.2. siRNA-mediated downregulation
Lipofectamine RNAiMAX (Invitrogen, Darmstadt, Germany) was
used to transfect SZ95 sebocytes at 40% conﬂuence in 6-well or
96-well plates with siRNAs for EGFR, ERBB2, ERBB3 or with a neg-
ative control siRNA (Silencer Select, Ambion, Austin, TX, USA). 24 h
after transfection, cells were induced to synthesize lipids by adding
LA to the culture medium as described above. The cells were
allowed to differentiate for 48 h, harvested with ice-cold PBS and
stored as cell pellets at 80 C for the lipid analysis or dissolved
in protein lysis buffer for Western blot analysis.
2.3. Quantitative RT-PCR
Total RNA was isolated with TRIzol reagent (Invitrogen) and
1 lg of RNA samples were reverse-transcribed in a ﬁnal volume
of 20 ll using RevertAid Reverse Transcriptase (Thermo Scientiﬁc,
Schwerte, Germany) according to the manufacturer’s instructions.
Quantitative RT-PCR was carried out in a LightCycler 480
(Roche, Mannheim, Germany) using the primers listed in Table 1
(0.5 lM), 1 ll cDNA, 0.2 lM probe (Universal ProbeLibrary Set,
Roche), and the LightCycler 480 Probes Master (Roche) in a ﬁnal
volume of 10 ll. Cycle conditions were 95 C for 5 min for the ﬁrst
cycle, followed by 45 cycles of 95 C for 10 s, 60 C for 15 s, and
72 C for 1 s. Transcript copy numbers were normalized to pep-
tidylprolyl isomerase A (PPIA) mRNA copies. The DCt value of the
sample was determined by subtracting the average Ct value of
the target gene from the average Ct value of the PPIA gene. For each
primer pair we performed no-template and no-RT control assays,
which produced negligible signals that were usually greater than
40 in Ct value. Experiments were performed in duplicates for each
sample.
2.4. Western blot analysis
Protein was extracted using Laemmli-extraction-buffer, and the
protein concentration was estimated via bicinchoninic acid protein
assay. 30 lg of total protein were separated by 12% SDS–PAGE and
transferred to PVDF membranes (Millipore, Schwalbach, Germany)
by semidry blotting. Membranes were blocked in 5% w/v fat-free
milk powder (Roth, Karlsruhe, Germany) for 1 h at room tempera-
ture. After washing in Tris-buffered saline solution with 1%
Tween20 (Sigma, Taufkirchen, Germany), membranes were incu-
bated over night at 4 C in 5% w/v BSA (Sigma) with the appropri-
ated primary antibody. Primary antibodies were rabbit anti-EGFR
(1005), rabbit anti-ERBB2 (C-18), rabbit anti-ERBB3 (C-17)(1:500; Santa Cruz, Heidelberg, Germany) and rabbit anti-A
Tubulin (1:5000) (Cell Signaling, Frankfurt, Germany, #2125).
After washing, membranes were incubated in 5% w/v fat-free milk
powder with a horseradish peroxidase-labeled secondary antibody
donkey anti-rabbit (1:2000; NA934V, GE Healthcare, Munich,
Germany). Signals were detected using an enhanced chemilumi-
nescence detection reagent (GE Healthcare) and appropriated
X-ray ﬁlms (GE Healthcare).
1378 M. Dahlhoff et al. / FEBS Letters 589 (2015) 1376–13822.5. Lipid analysis
For the Nile red assay, SZ95 sebocytes were washed twice with
PBS, stained for 10 min with DAPI (2.5 lg/ml, Sigma), washed once
with PBS and then stained with AdipoRed (Lonza, Walkersville,
MD, USA) according to the manufacturer’s instructions. After
10 min, the ﬂuorescence (488 nm) was measured and quantiﬁed
using the Operetta high content screening system (Perkin Elmer,
Waltham, MA).
Lipid composition of sebocyte cells was investigated by analyz-
ing crude lipid extracts with rapid resolution-reversed phase–high
performance liquid chromatography coupled with electrospray
ionization and time of ﬂight mass spectrometry (RR-RP/HPLC-
ESI–ToF/MS) as previously described [19]. Brieﬂy, lipids were
extracted from 2  106 SZ95 sebocytes for each sample with abso-
lute ethanol containing 0.025% buthylated hydroxytoluene (BHT,
Sigma–Aldrich, St. Louis, MO, USA) to prevent autoxidation.
N-lauroyl-D-erythro-sphingosylphosphorylcholine (SM 12:0, Avanti
Polar Lipids Inc., Alabaster, AL, USA), deuterated cholesterol-
2,2,3,4,4,6-d6 (d6CH), and glyceryl-d5-trihexadecanoate (d5TG
48:0) (CDN isotopes Inc., Pointe-Claire, Quebec, Canada) were
added as the internal standards (ISTDs) at a ﬁnal concentration of
5, 50 and 10 lM, respectively, to control recovery of lipids,
analytical performance and to calculate the relative abundance of
detected lipids. The concentrated ethanol phase was extracted with
ethyl acetate. Proﬁles of intact cell lipids were acquired in positive
ion mode. Two experiments performed in duplicate were analyzed.
Accurate mass spectra were acquired in the m/z mass rangeVehicle
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Fig. 1. Abundance and regulation of EGFR/ERBB family members in SZ95 sebocytes. (A) A
(n = 5 samples/group). (B) Expression of the receptors in SZ95 sebocytes treated with ve
and PLIN3 in undifferentiated cells (vehicle) and cells induced to differentiate by culture
detection of tubulin as a loading control. (D) Analysis of EGFR ligand transcript levels by q
EGFR ligands in sebocytes treated with vehicle or LA for 48 h (n = 5 samples/group). Data
vehicle and LA-treated sebocytes (⁄⁄P < 0.01, ⁄⁄⁄P < 0.001).120–1200. The molecular features extraction algorithm was used
to extract individual molecular species by their accurate mass
detected with the ToF MS. Lists of molecular features, which were
the detected species characterized by accurate mass, isotopic pat-
tern and absolute abundance, were produced from each analyzed
sample and converted into exchange ﬁles then processed with
Mass Proﬁler Professional 12 (MPP 12, see below). Molecular fea-
tures shared by the analyzed samples were aligned by their reten-
tion time (RT) in the chromatographic run, and accurate mass axis
in order to compare their expression across the different experi-
mental conditions. Compounds detected in the different samples
and presenting consistent RT (shift below 6% of the RT) and accu-
rate mass (mass error below 6 ppm) were assigned as the same
molecular species. Relative abundance of individual features was
obtained by normalizing their peak area by the area of the ISTDs.
Compound identiﬁcation and annotation were performed on the
basis of in house databases, built with previously collected MS data
and using the METLIN Personal Metabolite Database by means of
the IDbrowser tool, and the Molecular Formula Generator algo-
rithm. The Human Metabolome Database (http://www.hmdb.ca/)
and LIPIDMAPS (http://www.lipidmaps.org/) were used to conﬁrm
and extend the identiﬁcation. Equipment, data and statistical anal-
ysis packages were from Agilent Technologies, CA, USA.
2.6. Data pretreatment and statistical analysis
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the undifferentiated cells and compared by Student’s t-test
(GraphPad Prism version 5.0 for Windows, GraphPad Software,San Diego, CA, USA). Data are presented as means ± S.D. or
box-plots with median. Group differences were considered to be
statistically signiﬁcant if P < 0.05. Pretreatment of analytical data
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1380 M. Dahlhoff et al. / FEBS Letters 589 (2015) 1376–1382consisted of RT and m/z alignment and normalization by ISTDs,
baselining toward blank runs to remove background noise, and
logarithmic transformation of normalized abundance. Statistical
evaluation of the aligned and normalized HPLC–ToF/MS data was
performed using univariate analysis, including Student t-test and
one-way analysis of variance (ANOVA) using the MPP 12 package.
3. Results
3.1. Expression of EGFR/ERBB receptors and EGFR ligands in sebocytes
We employed quantitative RT-PCR to characterize the expres-
sion of the EGFR/ERBB system in SZ95 sebocytes, a widely
employed sebocyte cell line [18]. Among the receptors, EGFR
showed the highest expression level, ERBB2 and ERBB3 transcript
levels was considerably less frequent, and no ERBB4 expression
could be detected (Fig. 1A). To evaluate relative changes in recep-
tor expression during differentiation, we treated SZ95 sebocytes
with the essential fatty acid LA for 48 h, an efﬁcient method to
induce sebaceous lipogenesis. As shown in Fig. 1B, LA treatment
signiﬁcantly reduced the transcript levels of all three receptors,
and this effect was conﬁrmed, at least for ERBB2 and ERBB3, at
the protein level (Fig. 1C). The evaluation of the transcript levels
of the seven EGFR ligands [20] by qRT-PCR demonstrated that
TGFA was the most abundantly expressed ligand, followed by
AREG, EREG, HBEGF, EGF, BTC, and EPGN (Fig. 1D). Treatment with
LA resulted in the upregulation of AREG, HBEGF, and EPGN levels,
reduced BTC levels, and unchanged transcript abundance of TGFA,
EREG, and EGF (Fig. 1E).3.2. Downregulation of EGFR/ERBB has receptor-speciﬁc effects on
sebaceous lipogenesis in SZ95 sebocytes
We employed siRNA-mediated downregulation to assess the
importance of EGFR/ERBB receptors during sebaceous lipogenesis.
Transfection of SZ95 sebocytes with speciﬁc siRNAs resulted in
almost complete depletion of the corresponding receptor, in con-
trast to untreated cells or cells transfected with a negative control
siRNA (Fig. 2A). Quantitative RT-PCR conﬁrmed a statistically sig-
niﬁcant, substantial reduction in the transcript levels of the corre-
sponding receptor (Fig. 2B). Interestingly, downregulation of
ERBB3 was accompanied by an upregulation of EGFR and ERBB2,
possibly as a compensatory mechanism (Fig. 2B).
Next, the Operetta system was employed for quantifying the
total lipid amount in Nile red-stained cells. In vehicle-treated
SZ95 sebocytes, downregulation of EGFR and ERBB3 resulted in a
signiﬁcant increase in the total cellular lipid amount, while down-
regulation of ERBB2 did not affect this parameter (Fig. 3A). In LA-
treated cells, in contrast, no changes in the lipid amount was
observed, independently of the siRNA employed (Fig. 3B). To inves-
tigate in greater detail the impact of EGFR/ERBB downregulation
on the lipid composition of vehicle-treated SZ95 sebocytes, we
employed a method based on rapid resolution reversed phase high
performance liquid chromatography coupled to electrospray–time
of ﬂight mass spectrometry (RR-RP/HPLC-ESI–ToF/MS), which
allows for the simultaneous detection of several hundreds of neu-
tral lipid species in their intact form. As shown in Fig. 3C, a total of
57 species were found to be modiﬁed in the EGFR/ERBB siRNA-
treated samples compared to the control siRNA-treated samples.
Furthermore, 16 samples were signiﬁcantly modiﬁed in common
by EGFR, ERBB2 or ERBB3. Downregulation of EGFR and ERBB3
resulted in the induction of several speciﬁc triglycerides (TGs), par-
ticularly of those bearing a total of 48–58 carbon atoms in the side
fatty acids (Fig. 3D). ERBB2 downregulation did not affect TG abun-
dance, thus conﬁrming the Nile red data. In contrast, ERBB2 down-
regulation had a prominent effect in inducing the relative amount
of cholesteryl esters (CEs), although CE species were also increased
in SZ95 sebocytes treated with EGFR or ERBB3 siRNAs (Fig. 3E).
Cholesterol levels were not modiﬁed in any of the studied condi-
tions (data not shown).3.3. Downregulation of EGFR/ERBB differentially affects the expression
of sebaceous lipogenesis markers in SZ95 sebocytes
Next, we assessed by RT-qPCR whether loss of EGFR/ERBB
receptors affected the expression of key markers of the intracellu-
lar pathways that govern lipogenic activity. Transcripts encoding
sterol regulatory element-binding protein-1 (SREBF1), a transcrip-
tion factor that regulates numerous genes involved in lipid
biosynthesis were found signiﬁcantly upregulated following
downregulation of EGFR, ERBB2, and ERBB3 (Fig. 4A–C).
Consistently, expression of the FAS, which is a SREBF1 target gene,
was signiﬁcantly upregulated (Fig. 4A–C). The expression of the
other examined genes was unchanged in EGFR-downregulated
cells (Fig. 4A). We detected a reduction in the transcript levels of
FADS2 and DGAT2, concomitantly to an increase in PLIN2 transcript
levels in SZ95 cells in which ERBB2 was downregulated (Fig. 4B). In
ERBB3-depleted cells, we observed an upregulation of all examined
markers (Fig. 4C).4. Discussion
Using the SZ95 cell line, we showed that sebocytes express
EGFR, ERBB2 and ERBB3, while no ERBB4 expression was detected.
This is in agreement to previous reports that ERBB4 expression is
M. Dahlhoff et al. / FEBS Letters 589 (2015) 1376–1382 1381not detectable in human [21,22] or mouse [9] epidermis, and also
not in human keratinocyte cell lines such as HaCaT [23] and A431
[24]. Notably, expression of all receptors was downregulated when
lipogenesis was induced in SZ95 cells by adding LA to the culture
medium. Changes in EGFR expression during keratinocyte prolifer-
ation and differentiation have been previously documented in a
number of studies (reviewed in [25]), and it has been also shown
that ERBB2 and ERBB3 expression is modulated during ker-
atinocyte differentiation [26]. Similarly, EGFR ligand expression is
affected by EGFR activation [27] and by induction of differentiation
[22] in keratinocytes. Furthermore, in agreement to our data, it was
shown that EGFR and ERBB2 are downregulated during the differ-
entiation of preadipocytes [28]. Furthermore, Nile red staining and
quantitative analysis of the emitted ﬂuorescence revealed that
siRNA-mediated downregulation of EGFR and ERBB3 in vehicle-
treated SZ95 sebocytes signiﬁcantly increase the total cellular lipid
amount. This observation, allied to the downregulation of EGFR/
ERBBs in LA-treated cells, suggest that EGFR signaling normally
inhibits sebaceous lipogenesis. As SZ95 cells express signiﬁcant
amounts of EGFR ligands such as TGFA, AREG, and EREG, tonic
autocrine receptor activation is likely to occur in vitro. While auto-
crine EGFR activation is also likely to happen in SG in the skin,
EGFR ligands may also stem from other cell types as ﬁbroblasts
or keratinocytes in vivo. Notably, the epidermis is a rich source
of different EGFR ligands, and their experimental loss or overabun-
dance is associated with a variety of pathological changes [25].
In contrast, no changes in the lipid amount were observed,
independently of the siRNA employed, in LA-treated cells. The lat-
ter observation may indicate that LA treatment represents a very
potent stimulus that can hardly be inﬂuenced by downregulation
of a single EGFR/ERBB family member. The effects of EGFR/ERBB
downregulation on the lipid accumulation in vehicle-treated
SZ95 sebocytes were largely conﬁrmed by a spectrometry-based
method: Downregulation of EGFR and ERBB3 resulted in the induc-
tion of several speciﬁc TGs, particularly of those bearing 48–58 car-
bon atoms in the side fatty acids, while ERBB2 downregulation did
not affect TG abundance. Since TG represent 50% of sebaceous
lipids [4,29], these changes are important for both total sebaceous
lipids and lipid composition. In contrast, EGFR, ERBB2 and ERBB3
downregulation induced the relative amount of CEs.
These effects were accompanied by receptor type-speciﬁc
changes in the expression of sebocyte lipogenesis markers.
Signiﬁcant upregulation of SREBF1 and its target gene FAS was a
common feature of the EGFR/ERBB downregulation. SREBF1, a
transcription factor of the SREBP family [30], is known to play a
crucial role in the lipogenic stimulus in sebocytes [31]. One of
the primary mechanisms of the lipid synthesis regulation by
SREBF1 is the induction of fatty acid synthesis and desaturation
through FAS and SCD1 expression [32,33]. Expression levels of
transcripts for enzymes involved in the biotransformation of FAs,
mainly desaturases, and in the lipid storage were differently regu-
lated following EGFR/ERBB downmodulation. The effects of the
ERBB2 siRNA on the expression of FADS2 and PLIN2, an enzyme
that catalyses the formation of sapienic acid [34] and a lipid dro-
plet-associated protein that protects cells from lipolysis [19],
respectively, remain to be explained. In ERBB3-depleted cells, we
observed an upregulation of DGAT2, FADS2, PLIN2, SCD1 and
SCD5. These extensive changes are compatible with the induction
of TG and CE synthesis after ERBB3 downregulation.
Alternatively, they may represent a consequence of the observed
compensatory upregulation of EGFR and ERBB2 transcripts in
ERBB3 siRNA-treated cells, and therefore an experimental artefact.
In contrast, a reduction in the transcript levels of DGAT2 and FADS2,
concomitantly to an increase in PLIN2 transcript levels were
observed in ERBB2-downregulated SZ95 sebocytes. As DGAT2 is
an essential enzyme for TG synthesis [35], its downregulationmay explain while downregulation of ERBB2 (in contrast to EGFR
and ERBB3) did not enhance TG synthesis in SZ95 sebocytes.
In summary, our study reveals that sebocytes abundantly
express EGFR, with lower levels of ERBB2 and ERBB3. These recep-
tors are downregulated following induction of lipid synthesis by
addition of LA to the culture medium, thus supporting the concept
that regulation of EGFR/ERBB expression represents a mechanism
for switching from a mitogenic to a differentiating phenotype.
Importantly, siRNA-mediated downregulation revealed speciﬁc
effects of these receptors in the accumulation of TGs and CEs,
and in the expression of key markers of sebaceous lipid synthesis.
Thus, EGFR and ERBB2/3 may represent attractive targets for mod-
ulating sebaceous lipogenesis, a key factor in the pathogenesis of
sebaceous gland-associated skin diseases, such as acne.
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